Upsher-Smith Laboratories LLC, a subsidiary of Bora Pharmaceuticals Co. Ltd., announced the launch of cyclosporine ophthalmic emulsion 0.05%, the therapeutic equivalent to the reference listed drug, cyclosporine ophthalmic emulsion 0.05% (Restasis; Allergan, an AbbVie company). Bora received US Food and Drug Administration (FDA) approval of its abbreviated new drug application for the product in January 2026.

The product is available in 30-count and 60-count 0.4 mL single-use vials

"The launch of cyclosporine ophthalmic emulsion reflects Upsher-Smith's continued momentum in expanding and diversifying its US portfolio," said Jim Maahs, senior vice president, head of Upsher-Smith Commercial. "This addition strengthens our ophthalmic offerings and reflects our focus on bringing medicines to market that support the evolving needs of our customers, health care providers, and patients."